載入...

Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer

The treatment of metastatic castration resistant prostate cancer (mCRPC) has evolved markedly since the approval of docetaxel-based therapy in 2004. Since that time, 3 distinct agents have gained approval for use in the mCRPC setting, namely sipuleucel-T, cabazitaxel and abiraterone. Even more recen...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Pal, Sumanta K., Lewis, Brian, Sartor, Oliver
格式: Artigo
語言:Inglês
出版: 2012
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3845898/
https://ncbi.nlm.nih.gov/pubmed/23084533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ucl.2012.07.013
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!